JP5948648B2 - 安定化されたエペリゾンを含有する徐放性製剤 - Google Patents

安定化されたエペリゾンを含有する徐放性製剤 Download PDF

Info

Publication number
JP5948648B2
JP5948648B2 JP2014536967A JP2014536967A JP5948648B2 JP 5948648 B2 JP5948648 B2 JP 5948648B2 JP 2014536967 A JP2014536967 A JP 2014536967A JP 2014536967 A JP2014536967 A JP 2014536967A JP 5948648 B2 JP5948648 B2 JP 5948648B2
Authority
JP
Japan
Prior art keywords
acid
eperisone
sustained
release
release preparation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2014536967A
Other languages
English (en)
Japanese (ja)
Other versions
JP2014530250A (ja
Inventor
リー、チャン−キョー
パク、サン−ゲウン
Original Assignee
ナビファーム．カンパニー リミテッド
ナビファーム．カンパニー リミテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ナビファーム．カンパニー リミテッド, ナビファーム．カンパニー リミテッド filed Critical ナビファーム．カンパニー リミテッド
Publication of JP2014530250A publication Critical patent/JP2014530250A/ja
Application granted granted Critical
Publication of JP5948648B2 publication Critical patent/JP5948648B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4453—Non condensed piperidines, e.g. piperocaine only substituted in position 1, e.g. propipocaine, diperodon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Biophysics (AREA)
  • Pain & Pain Management (AREA)
  • Molecular Biology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Biomedical Technology (AREA)
  • Rheumatology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2014536967A 2011-10-18 2012-03-28 安定化されたエペリゾンを含有する徐放性製剤 Active JP5948648B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
KR10-2011-0106388 2011-10-18
KR1020110106388A KR101156054B1 (ko) 2011-09-05 2011-10-18 안정한 에페리손 함유 서방성 의약조성물
PCT/KR2012/002288 WO2013058450A1 (ko) 2011-10-18 2012-03-28 안정화된 에페리손 의약 조성물 및 이를 함유하는 서방성 제제

Publications (2)

Publication Number Publication Date
JP2014530250A JP2014530250A (ja) 2014-11-17
JP5948648B2 true JP5948648B2 (ja) 2016-07-06

Family

ID=48141658

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2014536967A Active JP5948648B2 (ja) 2011-10-18 2012-03-28 安定化されたエペリゾンを含有する徐放性製剤

Country Status (6)

Country Link
JP (1) JP5948648B2 (pt)
KR (1) KR101156054B1 (pt)
CN (1) CN103889455B (pt)
BR (1) BR112014009506B1 (pt)
MX (1) MX346661B (pt)
WO (1) WO2013058450A1 (pt)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101230178B1 (ko) 2010-06-10 2013-02-06 주식회사 네비팜 골다공증 예방 또는 치료용 조성물 및 이의 제조방법
KR101832842B1 (ko) * 2012-01-13 2018-02-27 한미약품 주식회사 안정성이 향상된 에페리손 또는 이의 약학적으로 허용 가능한 염 및 특정 산성화제를 포함하는 약학 조성물
KR101497354B1 (ko) * 2013-03-29 2015-03-02 초당약품공업 주식회사 활성 성분으로 에페리손을 함유하는 서방성 제제 조성물
KR20140118410A (ko) * 2013-03-29 2014-10-08 초당약품공업 주식회사 저장 및 pH 안정성이 개선된 에페리손 의약 조성물
KR101799321B1 (ko) 2016-08-29 2017-11-20 초당약품공업 주식회사 에페리손 서방성 미립구와 아세클로페낙 복합제제
KR101760278B1 (ko) 2016-08-29 2017-07-21 초당약품공업 주식회사 에페리손을 유효 성분으로 함유하는 서방성 미립구의 제조방법
WO2018044020A1 (ko) * 2016-08-29 2018-03-08 초당약품공업 주식회사 에페리손 서방성 미립구의 제조방법 및 에페리손 서방성 미립구와 아세클로페낙 복합제제
KR102254307B1 (ko) 2019-04-03 2021-05-21 위더스제약주식회사 보관 안정성이 향상된 에페리손 약제학적 조성물
KR102444073B1 (ko) * 2020-01-06 2022-09-16 (주)휴온스 안정성이 향상된 메틸에르고메트린말레산염 함유 약제학적 제제 및 이의 제조방법

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR0163199B1 (ko) * 1990-05-24 1998-12-01 다이도 나오가따 서방성 좌제
JP3525225B2 (ja) * 1992-11-09 2004-05-10 積水化学工業株式会社 エペリゾンまたはトルペリゾン経皮吸収テープ剤またはパッチ剤、およびその製造方法
CA2347104A1 (en) 1998-10-26 2000-04-05 Tanabe Seiyaku Co., Ltd. Sustained-release particles
JP2000143510A (ja) * 1998-11-16 2000-05-23 Taisho Pharmaceut Co Ltd 外用組成物
AT500144A1 (de) * 2004-03-05 2005-11-15 Sanochemia Pharmazeutika Ag Tolperison enthaltende, pharmazeutische zubereitung mit steuerbarer wirkstofffreisetzung zur oralen verabreichung
DE102005014080B4 (de) * 2005-03-21 2007-11-22 Birds Pharma Gmbh Berolina Innovative Research & Development Services Additionssalze des Tolperison, Verfahren zu deren Herstellung, Verwendung derselben und diese enthaltende Arzneimittel
US8173152B2 (en) * 2006-03-24 2012-05-08 Auxilium Us Holdings, Llc Stabilized compositions containing alkaline labile drugs
AT505225A1 (de) * 2007-04-26 2008-11-15 Sanochemia Pharmazeutika Ag 0erfahren zur herstellung von hoch reinem 2,4'-dimethyl-3-piperidino-propiophenon (tolperison), dieses enthaltende pharmazeutische zusammensetzungen, sowie tolperison enthaltende wirkstoffformulierungen
HUP0700828A2 (en) * 2007-12-20 2010-01-28 Richter Gedeon Nyrt Transdermal pharmaceutical compositions containing tolperisone alone and in combination
EA201171109A1 (ru) * 2009-03-09 2012-03-30 Динеш Шантилал Пател Новая композиция замедленного высвобождения соединений, выбранных из класса миорелаксантов центрального действия

Also Published As

Publication number Publication date
JP2014530250A (ja) 2014-11-17
CN103889455B (zh) 2017-12-05
KR101156054B1 (ko) 2012-06-20
WO2013058450A1 (ko) 2013-04-25
BR112014009506A2 (pt) 2017-05-09
MX2014004652A (es) 2015-03-05
MX346661B (es) 2017-03-28
BR112014009506B1 (pt) 2020-04-07
CN103889455A (zh) 2014-06-25

Similar Documents

Publication Publication Date Title
JP5948648B2 (ja) 安定化されたエペリゾンを含有する徐放性製剤
KR101752014B1 (ko) 고용량 및 저용량 약물들의 조합을 포함하는 구강붕해정 조성물
ES2667944T3 (es) Gránulos y comprimidos orodispersables que contienen oxicodona
JP6173521B2 (ja) ナルブフィンを含有する製剤及びそれらの使用
WO2006082523A2 (en) Pharmaceutical sustained release composition of metformin
PT1448235E (pt) Composições farmacêuticas orais de libertação controlada de 5,8,14-triazatetraciclo ( 10.3.1.0(2,11).0(4,9) ) - hexadeca-2(11),3,5,7,9-pentaeno.
US20230240999A1 (en) Novel fine particle coating (drug-containing hollow particle and method for manufacturing same)
WO2012110912A1 (en) Sustained release composition of memantine
US20240148693A1 (en) Composition, preparation method therefor, and use thereof
WO2012020301A2 (en) Oral controlled release pharmaceutical compositions of blonanserin
WO2010023690A2 (en) Prolonged release formulation of amisulpride
KR101171375B1 (ko) 난용성 약물을 함유하는 경구 제형
WO2012147101A2 (en) Pharmaceutical compositions of raltegravir, methods of preparation and use thereof
TW201201800A (en) A pharmaceutical controlled release composition of losartan
WO2013013351A1 (zh) 复方甲氧那明的速释-缓释渗透泵制剂
RU2669920C2 (ru) Фармацевтическая композиция с контролируемым высвобождением, основанная на прионовой кислоте
US20220249479A1 (en) Modified release formulation of a pyrimidinylamino-pyrazole compound, and methods of treatment
JP5919173B2 (ja) 徐放性塩酸アンブロキソール口腔内崩壊錠
JP4696210B2 (ja) イソソルビド‐５‐モノニトレートを有効成分とする徐放性錠剤及びその製造方法
TWI568455B (zh) 每日一次投藥之提供藥學及臨床效果之莫沙必利持續釋放製劑
JP2015508789A (ja) 医薬製剤
AU2021265311A1 (en) Novel multiparticulate pharmaceutical composition of tamsulosin and solifenacin

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20141014

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20150930

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20151006

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20160106

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20160510

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20160516

R150 Certificate of patent or registration of utility model

Ref document number: 5948648

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250